What to expect in the Tarsus Pharmaceuticals, Inc. interview process

Based on publicly available sources, Tarsus Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company headquartered in Irvine, California, founded in 2017. Operating in the pharmaceutical manufacturing sector with a focus on eye care and infectious diseases—notably developing therapies like the FDA-approved XDEMVY eye drop for Demodex Blepharitis—the company has experienced significant headcount growth. Workforce intelligence data shows its total global headcount grew from 149 employees in 2023 to approximately 390 employees by March 2026, supported by a distributed workforce spanning the United States, Switzerland, and the Netherlands.

Public data indicates that the company maintains an active recruitment footprint, reflecting its ongoing expansion, with active job postings increasing year-over-year. Tarsus has accumulated multiple workplace recognitions, including being certified as a Great Place To Work® for five consecutive years, named a USA TODAY Top Workplace for two consecutive years, and earning placements on the Orange County Register Top Workplaces and BioSpace Best Places to Work lists. Employee branding and public communications consistently emphasize a collaborative, purpose-driven culture focused on patient impact and team dedication, often utilizing the internal moniker "Tarsans" to describe its workforce.